161 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
. innovative solutions that address the world’s unmet health challenges. As we discover and develop life-saving or life-trans- forming medicines, we take our … , a global pharmaceutical company. This increase access to our innovative medicines to everyone acquisition enhanced our international footprint, who
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 May 23
Current report (foreign)
6:19am
to this innovative vaccine. We hope that it will lead to broader long-term adoption by endemic countries facing this serious public health challenge. We … are determined and proud to roll out such an innovative pricing model – a first in vaccine pricing – and to continue to deliver highly innovative, life
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
31 May 22
Current report (foreign)
6:14am
on Globalization 03
As explained later in this letter, we will invest in and support our ambition to provide patients in China with innovative medicines … and deliver innovative treatments to address patients’ greatest unmet medical needs. I am energized by the impact we are making for patients and our
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
21 Nov 19
Current report (foreign)
6:08am
, President, Plasma‐Derived Therapies Business Unit A New Dedicated Focus on Innovative, Sustainable Solutions for Plasma‐Derived Therapies 11:45 – 12:15 … – 13:45 Christophe Weber, President & CEO Takeda Translating Science into Highly Innovative, Life‐changing Medicines 13:45 – 14:15 Andy Plump, President
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
17 Dec 20
Current report (foreign)
6:01am
global brands and an exciting pipeline of innovative medicines. Our R&D engine continues to translate science into potentially life-changing … also developing innovative pricing and contract strategies. And we’re staying on top of rapid changes in technology and the delivery of health care
6-K
ae5w37q764
27 May 20
Current report (foreign)
6:12am
6-K
e6t 0qpgn
1 Apr 20
Current report (foreign)
6:21am
6-K
1sbl7 n2j3y1c7q
24 Jun 20
Current report (foreign)
6:09am
6-K
85j57
6 Oct 21
Current report (foreign)
6:03am
6-K
4k2e sc4pmh
14 Jan 20
Current report (foreign)
6:56am
6-K
EX-99.1
h8tc2rfqkoxyzu7gj
28 May 21
Current report (foreign)
6:04am
6-K
uibk4h4 1r
14 Nov 19
Current report (foreign)
6:14am
6-K
6s5tst
6 Apr 20
Current report (foreign)
6:46am
6-K
EX-99.1
xt22g
14 Nov 19
Current report (foreign)
6:26am
6-K
EX-99.1
eqrq87w7 6xoav
11 Jan 22
Current report (foreign)
6:02am
6-K
EX-99.1
lk322zk3
29 Jun 21
Current report (foreign)
7:38am
6-K
5ugc4
7 Aug 20
Current report (foreign)
6:02am
6-K
EX-99.1
7d799oo qi
6 Apr 21
Current report (foreign)
6:29am
6-K
EX-99.1
s10 fy40nz496
21 Dec 22
Current report (foreign)
6:01am
SC TO-T/A
EX-99
ppwuai8pqygsa1h
6 Jun 18
Third party tender offer statement (amended)
4:39pm